Literature DB >> 1854885

A study of the myeloid differentiation antigens of the peripheral blood neutrophil granulocytes in the different evolutive phases of chronic myeloid leukemia.

M Rozman1, F Cervantes, C Rozman.   

Abstract

To ascertain whether progression from the chronic to the accelerated and blastic phases of chronic myeloid leukemia (CML) is associated with the loss of the myeloid differentiation antigens of the neutrophil granulocytes (NG), we analyzed two monoclonal antibodies (PMN 31D8 and PMN 13F6) recognizing normal peripheral blood NG membrane antigens in 49 patients in different evolutive stages of CML. Since five patients were studied twice, a total of 54 studies were carried out. Fourteen patients were evaluated at diagnosis, 12 in the controlled chronic phase within 1 year from diagnosis, 14 in the advanced chronic phase (median evolution 3.25 years), and 14 in the accelerated (five cases) or blastic (nine cases) phases. Fourteen normal subjects served as a control group. At diagnosis, a significant decrease in the positivity for both antigens was observed with respect to controls, probably due to the circulation of incompletely mature NG. In the early chronic phase the values were within the normal range, whereas a significant decrease was registered in the advanced chronic phase and especially in the accelerated/blastic phase. A negative correlation between the NG positivity for both markers and the time elapsed from the moment of obtaining the initial control of the disease was found, suggesting that a progressive loss of the myeloid antigens of the NG occurs during the evolutive course of CML. These results seem to confirm the usefulness of the NG myeloid differentiation antigen study as an evolutive parameter in CML.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1854885     DOI: 10.1007/bf01729836

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  15 in total

1.  Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

Authors:  J M Goldman; R P Gale; M M Horowitz; J C Biggs; R E Champlin; E Gluckman; R G Hoffmann; S J Jacobsen; A M Marmont; P B McGlave
Journal:  Ann Intern Med       Date:  1988-06       Impact factor: 25.391

2.  Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).

Authors:  J L Cordell; B Falini; W N Erber; A K Ghosh; Z Abdulaziz; S MacDonald; K A Pulford; H Stein; D Y Mason
Journal:  J Histochem Cytochem       Date:  1984-02       Impact factor: 2.479

Review 3.  Functional and biochemical phenotype in relation to cellular age of differentiated neutrophils in chronic myeloid leukaemia.

Authors:  B Pedersen
Journal:  Br J Haematol       Date:  1982-07       Impact factor: 6.998

Review 4.  Chronic myelogenous leukemia--new concepts (first of two parts).

Authors:  H P Koeffler; D W Golde
Journal:  N Engl J Med       Date:  1981-05-14       Impact factor: 91.245

5.  A multivariate analysis of prognostic factors in chronic myeloid leukemia.

Authors:  F Cervantes; C Rozman
Journal:  Blood       Date:  1982-12       Impact factor: 22.113

6.  Prognostic discrimination in "good-risk" chronic granulocytic leukemia.

Authors:  J E Sokal; E B Cox; M Baccarani; S Tura; G A Gomez; J E Robertson; C Y Tso; T J Braun; B D Clarkson; F Cervantes
Journal:  Blood       Date:  1984-04       Impact factor: 22.113

7.  Characteristics of accelerated disease in chronic myelogenous leukemia.

Authors:  H M Kantarjian; D Dixon; M J Keating; M Talpaz; R S Walters; K B McCredie; E J Freireich
Journal:  Cancer       Date:  1988-04-01       Impact factor: 6.860

8.  A neutrophil membrane marker reveals two groups of chronic myelogenous leukemia and its absence may be a marker of disease progression.

Authors:  J I Gallin; R J Jacobson; B E Seligmann; J A Metcalf; J H McKay; R A Sacher; H L Malech
Journal:  Blood       Date:  1986-08       Impact factor: 22.113

9.  Staging of chronic myeloid leukaemia.

Authors:  S Tura; M Baccarani; G Corbelli
Journal:  Br J Haematol       Date:  1981-01       Impact factor: 6.998

10.  Loss of myeloid differentiation antigens precedes blastic transformation in chronic myelogenous leukemia.

Authors:  M B Todd; J A Waldron; T A Jennings; L S Rome; S D Markowitz; T R Holford; J P Gardner; J P Wolak; H L Malech
Journal:  Blood       Date:  1987-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.